Skandinaviska Enskilda Banken AB publ decreased its position in United Therapeutics Co. (NASDAQ:UTHR – Get Rating) by 71.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 200 shares of the biotechnology company’s stock after selling 500 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in United Therapeutics were worth $42,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can boosted its stake in shares of United Therapeutics by 8.9% in the 1st quarter. Great West Life Assurance Co. Can now owns 28,326 shares of the biotechnology company’s stock valued at $5,244,000 after purchasing an additional 2,320 shares during the last quarter. Canada Pension Plan Investment Board boosted its stake in United Therapeutics by 229.6% in the first quarter. Canada Pension Plan Investment Board now owns 2,063 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 1,437 shares during the last quarter. Prudential PLC acquired a new stake in United Therapeutics during the 1st quarter worth $1,160,000. Zions Bancorporation N.A. bought a new stake in shares of United Therapeutics during the 1st quarter valued at $66,000. Finally, Covestor Ltd lifted its stake in shares of United Therapeutics by 187.5% in the 1st quarter. Covestor Ltd now owns 877 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 572 shares during the period. 95.63% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In related news, Director Judy D. Olian sold 1,010 shares of the stock in a transaction dated Friday, December 9th. The stock was sold at an average price of $282.00, for a total transaction of $284,820.00. Following the completion of the transaction, the director now directly owns 7,655 shares in the company, valued at $2,158,710. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Martine A. Rothblatt sold 8,000 shares of the business’s stock in a transaction on Wednesday, February 22nd. The shares were sold at an average price of $246.77, for a total value of $1,974,160.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $32,080.10. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Judy D. Olian sold 1,010 shares of the stock in a transaction on Friday, December 9th. The stock was sold at an average price of $282.00, for a total transaction of $284,820.00. Following the transaction, the director now owns 7,655 shares of the company’s stock, valued at approximately $2,158,710. The disclosure for this sale can be found here. Insiders have sold a total of 207,420 shares of company stock worth $54,432,209 over the last three months. Corporate insiders own 12.40% of the company’s stock.
United Therapeutics Stock Up 0.6 %
United Therapeutics (NASDAQ:UTHR – Get Rating) last posted its quarterly earnings data on Wednesday, February 22nd. The biotechnology company reported $2.67 EPS for the quarter, missing the consensus estimate of $4.12 by ($1.45). The company had revenue of $491.50 million during the quarter, compared to the consensus estimate of $519.20 million. United Therapeutics had a net margin of 37.56% and a return on equity of 16.30%. The company’s revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.35 earnings per share. On average, equities research analysts anticipate that United Therapeutics Co. will post 18.65 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the company. UBS Group assumed coverage on United Therapeutics in a research note on Tuesday, December 6th. They set a “buy” rating and a $320.00 price objective for the company. LADENBURG THALM/SH SH lowered their price target on United Therapeutics from $295.00 to $285.00 in a research note on Thursday. Oppenheimer increased their price target on shares of United Therapeutics from $325.00 to $375.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. Wedbush boosted their price objective on shares of United Therapeutics from $250.00 to $305.00 in a report on Thursday, November 3rd. Finally, Morgan Stanley cut their target price on shares of United Therapeutics from $330.00 to $320.00 and set an “overweight” rating on the stock in a report on Thursday. Two analysts have rated the stock with a sell rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $291.55.
About United Therapeutics
United Therapeutics Corp. operates as a biotechnology company engaged in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma. It is involved in the development of novel pharmaceutical therapies and technologies that expand the availability of transplantable organs.
Recommended Stories
- Get a free copy of the StockNews.com research report on United Therapeutics (UTHR)
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
- Analysts Holding As Pfizer Waits On Two Phase 3 Studies
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR – Get Rating).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
